OBJECTIVES: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progression in Huntington's disease (HD). This study investigated associations between lifestyle factors and NfL levels in HD mutation carriers compared to healthy age- and sex-matched controls. MATERIALS AND METHODS: Participants included 29 HD mutation carriers and 15 healthy controls. Associations between serum NfL concentrations and lifestyle factors, including cardiorespiratory fitness, social network size and diversity, physical activity, cognitive reserve, smoking status, and alcohol consumption, were examined using a stepwise multivariable linear regression model. RESULTS: Higher NfL levels were associated with lower cognitive reserve, soc...
There is an unmet need to reliably and non-invasively monitor disease progression in preclinical Hun...
Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and to...
IntroductionThe inclusion of premanifest Huntington's Disease (Pre-HD) subjects in clinical trials n...
Objective: Neurofilament light (NfL) protein in blood plasma has been proposed as a prognostic bioma...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
INTRODUCTION:Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light...
INTRODUCTION: Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament ligh...
INTRODUCTION: Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament ligh...
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a CAG-repea...
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a CAG-repea...
There is an unmet need to reliably and non-invasively monitor disease progression in preclinical Hun...
Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and to...
IntroductionThe inclusion of premanifest Huntington's Disease (Pre-HD) subjects in clinical trials n...
Objective: Neurofilament light (NfL) protein in blood plasma has been proposed as a prognostic bioma...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
Objectives: Serum neurofilament light protein (NfL) is a promising marker of disease onset and progr...
INTRODUCTION:Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light...
INTRODUCTION: Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament ligh...
INTRODUCTION: Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament ligh...
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a CAG-repea...
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a CAG-repea...
There is an unmet need to reliably and non-invasively monitor disease progression in preclinical Hun...
Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and to...
IntroductionThe inclusion of premanifest Huntington's Disease (Pre-HD) subjects in clinical trials n...